Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer

By afschroeder • June 4, 2026

McGann KC, Woodhouse P, Chen H, Kammer MN, Holmes HM, Lopez C, Pass HI, Tsay JJ, Lenburg ME, Dubinett SM, Willey JC, Herman JG, Schabath MB, Khalil TA, Zou Y, Potter MH, Chen SC, Argaw SA, Meyers P, Fischer S, Tran C, Forero YJ, Antic S, Paez R, Lila E, Barón AE, Maldonado F, Deppen SA, Grogan EL. Leveraging Commercially Available Protein Assays as Biomarkers for Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2026 Jun 3:OF1-OF8. doi: 10.1158/1055-9965.EPI-25-2004. Epub ahead of print. PMID: 42233870.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Short-term outcomes of laparoscopic hiatal hernia repair with consecutive transoral incisionless fundoplication (cTIF): a prospective multicenter cohort study

Kolb JM, Canto MI, Parker B, Murray M, Brewer Gutierrez OI, Sharaiha RZ, Samarasena J, Thosani NC, Abu-Dayyeh BK, Janu P, Chang KJ, Nguyen NT.[...]

Intersecting Vulnerabilities: Depression, Suicidality, and HIV Risk Among Young Mothers in South Africa

Miller AP, Joseph Davey DL, Groenewald C, Filiatreau LM, Petersen Z, van Rooyen H, Essack Z. Intersecting Vulnerabilities: Depression, Suicidality, and HIV Risk Among Young[...]

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

Doroshow DB, Leal TA, Waqar SN, Borghaei H, Camidge DR, Dragnev KH, Edelman MJ, Gandara DR, Gerber DE, Gray JE, Hirsch FR, Husain H, Kozono[...]